CHAPTER 6

THE ROLE OF THE RENIN-ANGIOTENSIN SYSTEM IN HEPATIC FIBROSIS

J.S. LUBEL1, F.J. WARNER2, AND P.W. ANGUS1

1Department of Gastroenterology, Austin Health, Studley Road, Heidelberg, Melbourne, Victoria, Australia
2A.W. Morrow Gastroenterology and Liver Centre, Centenary Institute of Cancer Medicine and Cell Biology, University of Sydney, Sydney, Australia

1. INTRODUCTION

The liver is the second largest organ of the body and has a multitude of functions including carbohydrate and fatty acid metabolism, lipid transport, protein synthesis, storage of fat-soluble vitamins as well as detoxification and modification of compounds absorbed from the small intestine. It has a dual blood supply, with approximately 75% coming from the portal vein and 25% from the hepatic artery. The primary functional unit of the liver, the hepatic lobule, consists of a hexagonal zone of hepatic parenchyma surrounding a central hepatic vein with a number of portal tracts at the periphery which contain a terminal portal vein, bile ductule and hepatic arteriole. In the normal liver, blood flows from portal venous branches through specialised vascular channels called hepatic sinusoids, into the centrilobular hepatic vein. Hepatic sinusoids lack a distinct basement membrane and their endothelial cells have fenestrations which permit bidirectional free passage of solutes between the sinusoid and a sub-sinusoidal space known as the space of Disse. Hepatocytes, account for 70% of liver mass. These cells, which have microvilli on their basolateral surface to facilitate the interchange of nutrients with the sinusoid, are responsible for most of the metabolic and synthetic functions of the liver.

Chronic liver diseases disturb the normal structure and function of the liver by initiating hepatic fibrosis, a process that can eventually lead to progressive destruction of the normal hepatic architecture, loss of functioning hepatocytes and the development of liver cirrhosis. Angiotensin II, the main effector peptide of the renin-angiotensin system (RAS), is known to play an important role in chronic tissue injury and fibrosis in cardiovascular disease, chronic renal disease and diabetes. Its...
role in liver disease is less well established, however, recent studies indicate that, as in other organs, there is a renin-angiotensin-system within the liver and that locally generated angiotensin II plays an important role in the pathogenesis of liver injury and hepatic fibrosis. There is also evidence that in the fibrotic liver angiotensin II contributes to portal hypertension by stimulating contraction of perisinusoidal myofibroblasts and increasing sinusoidal resistance to portal flow. In addition to these local effects in the liver, the systemic RAS is activated in patients with advanced liver disease in response to mesenteric and systemic vasodilatation and has an important homeostatic role in maintaining adequate perfusion pressure to the kidney and other vital organs. It also contributes to renal sodium and water retention by releasing aldosterone and by stimulating secretion of antidiuretic hormone (ADH) from the posterior pituitary. These multiple roles of the RAS in liver disease have lead to major interest in the potential role of RAS antagonists in the prevention of liver fibrosis and the treatment of chronic liver disease and its complications.

2. PATHOGENESIS AND SIGNIFICANCE OF HEPATIC FIBROSIS

There are a large number of chronic liver diseases which cause hepatic fibrosis, including chronic viral hepatitis, alcoholic liver disease, non-alcoholic fatty liver disease, iron overload, diseases of the biliary tract and immune and metabolic liver diseases. Cirrhosis, the end stage of hepatic fibrosis, is characterised by the presence of extensive fibrotic septa separating and surrounding parenchymal nodules of regenerating hepatocytes. This disturbance of the normal hepatic architecture, in conjunction with vasoconstriction within the liver, impedes portal blood flow causing portal hypertension; this is the cause of many of the serious complications of cirrhosis including variceal bleeding, hepatic encephalopathy and ascites. Hepatitis B infection is the most common cause of cirrhosis worldwide. It is also the single most important cause of hepatocellular carcinoma, a disease responsible for nearly one third of the world’s cancer-related deaths (Lodato et al 2006).

Currently the only proven treatment for hepatic fibrosis is to remove the responsible injurious agent. Recent studies have shown that if this can be achieved, for example by eliminating viral replication in patients with chronic hepatitis B or C, hepatic fibrosis and even early stage cirrhosis can resolve. In patients with end-stage cirrhosis and liver failure, therapy is limited to symptom control and the prevention of life threatening complications such as variceal bleeding whilst cure can only be achieved with liver transplantation. Unfortunately despite major advances in antiviral therapy in recent years, many patients with chronic hepatitis do not respond to therapy. There are also a number of chronic liver diseases for which we currently do not have effective treatment. There is therefore an ongoing need to develop anti-fibrotic therapies that can be used to prevent fibrosis progression and the development of cirrhosis.

In the healthy liver, extracellular matrix (ECM) consists of collagens (predominantly type IV), glycoproteins, proteoglycans and glycosaminoglycans which provide a structural and functional framework for cellular migration, adhesion,
differentiation, proliferation and fibrogenic activation (Schuppan et al 2001). The space of Disse contains a delicate ECM with basement membrane-like composition, which permits solute diffusion from blood within the sinusoids to the surrounding cells. Hepatic fibrosis results in major changes to both the volume and composition of ECM. There are increases in the interstitial fibrillar collagens types I and III as well as non-fibrillar collagens (types IV and VI). Proteoglycan and glycosaminoglycan content also increases with the overall composition of the ECM changing from a low-density form to a denser more complex interstitial type. The collagenous and non-collagenous ECM content of the liver is increased by at least 3-5 fold in the cirrhotic liver. There is an associated loss of hepatocyte microvilli and structural changes to the sinusoidal endothelium which include loss of fenestrations, and deposition of fibrillar collagen in the space of Disse. These changes impair the transfer of sinusoidal nutrients to hepatocytes facilitating further hepatocyte injury and liver dysfunction.

The pattern of liver fibrosis ultimately depends on the site and intensity of injury. Hence, biliary obstruction results in bile ductular and periductular myofibroblast proliferation and initially produces periportal and then linking portal-portal fibrosis, viral hepatitis infection leads to portal and then portal-central fibrosis whilst disruption to hepatic venous outflow (as occurs in right ventricular failure or Budd Chiari syndrome) causes centrilobular hepatocyte necrosis and leads to centrilobular fibrosis (central to central septa) (Cassiman and Roskams 2002).

The cell type involved in hepatic fibrosis which has been most studied is the hepatic stellate cell (HSC). In part, this is due to the relative ease with which this cell can be isolated, purified and subcultured from both human and animal liver tissue. However, it has become clear from characterisation of cellular markers and electron microscopic studies that there is a diverse population of myofibroblasts within the liver that may also contribute to hepatic fibrosis. These include portal and septal myofibroblasts, cells residing in vessel walls, centrilobular myofibroblasts, and even marrow-derived HSC and myofibroblasts (Cassiman 2002, Kallis, Alison and Forbes 2006, Russo et al 2006). It is likely that the expression and importance of these myofibroblast subtypes vary in different human diseases and animal models.

The HSC normally resides in the space of Disse and is responsible for the storage of vitamin A. It is maintained in a quiescent, non-fibrogenic phenotype, in part, by the surrounding ECM composed predominantly of collagen IV (the collagen type present within the lamina densa of the basal lamina) and other non-collagenous components such as laminins. Following repetitive injury, changes in composition of the ECM in conjunction with the release of proinflammatory and profibrotic cytokines released from damaged hepatocytes, Kupffer cells and inflammatory cells, leads to a cascade of events culminating in the transformation of HSCs into activated myofibroblasts. These activated cells deposit extracellular matrix (ECM) but in addition express contractile proteins which enable them to modulate sinusoidal blood flow. HSCs are capable of producing a broad array of profibrotic and proinflammatory cytokines and chemokines including transforming growth factor beta-1 (TGFβ1), platelet derived growth factor (PDGF) and angiotensin II, all of which
can act in both a paracrine and autocrine manner to further perpetuate fibrosis (Friedman, Maher and Bissell 2000). As will be discussed below, recent data have shown that angiotensin II is involved in both the recruitment of inflammatory cells in response to liver injury (Sewnath et al. 2004) and transformation of hepatic stellate cells to their activated phenotype (Bataller et al. 2003).

Hepatic fibrosis is a dynamic process and the end result reflects a balance between pathways which lead to matrix accumulation and those which result in matrix degradation and fibrosis resolution. Matrix metalloproteinases (MMPs) capable of enzymatically degrading ECM are secreted from many liver cells including HSCs, Kupffer cells, hepatocytes and macrophages (Knittel et al. 1999). Certain MMPs (MMP-2, MMP-9 and MMP-3) may contribute to the pathogenesis of fibrosis by facilitating liver remodelling, altering both the quantity and the composition of the ECM. Other MMP subtypes (MMP-1, MMP-8) degrade fibrillar collagens in the fibrotic liver and therefore drive fibrosis resolution. Counterbalancing the effects of MMPs is a group of tissue inhibitors of metalloproteinases (TIMPs), which promote collagen and matrix deposition by preventing ECM degradation by matrix proteinases (Arthur 2000).

3. THE RENIN-ANGIOTENSIN SYSTEM

3.1. The Circulating Renin-Angiotensin System

Since the discovery of renin from kidney extracts by Tigerstedt and Bergman in 1898 our understanding of the intricacies of the organisation and function of the renin-angiotensin system (RAS) has expanded considerably (Tigerstedt R 1898, Basso and Terragno 2001). The circulating RAS is best known for its role as a regulator of blood pressure, and fluid and electrolyte homeostasis. Angiotensin II, the principal effector of the RAS, causes vasoconstriction directly by stimulating angiotensin type 1 (AT$_1$) receptors present on the surface of vascular smooth muscle cells and indirectly by potentiating the release of norepinephrine from postganglionic sympathetic fibres and stimulating antidiuretic hormone (ADH) release from the posterior pituitary. Long-term, angiotensin II regulates blood pressure by modulating sodium and water reabsorption through stimulation of AT$_1$ receptors in the kidney, and by stimulating the production and release of aldosterone from the adrenal glands. In addition, angiotensin II increases thirst sensation through stimulation of the subfornical organ within the diencephalon (Timmermans et al. 1992). Other effects that may be important in chronic organ damage include promotion of thrombosis, cardiac hypertrophy and angiogenesis.

The classical enzymatic pathway generating angiotensin II begins with the cleavage of the peptide bond between the leucine and valine residues on angiotensinogen producing the biologically inactive decapeptide, angiotensin I. This process is mediated by renin, an aspartic protease released from juxtaglomerular cells of the kidney into the circulation. The cascade continues with Angiotensin Converting Enzyme (ACE) found predominantly in the capillaries of the lung.
cleaving a dipeptide from the C-terminus of angiotensin I to form angiotensin II. The actions of angiotensin II are mediated via specific seven transmembrane G protein-coupled receptors. In humans, two angiotensin receptors (AT$_1$ and AT$_2$) with differing affinities for angiotensin II have been described (Timmermans et al 1992). Angiotensin II can further be cleaved at either its carboxy- or amino-terminus to produce biologically active angiotensin fragments. Thus, from the amino-terminus, Angiotensin III (2-8) can be formed following cleavage of the aspartate-arginine bond of angiotensin II by aminopeptidase A and angiotensin IV (3-8) can be formed following further cleavage of angiotensin III by aminopeptidase B and N (Ardaillou 1997). Angiotensin III shares many of the properties of angiotensin II with 40% of the pressor activity and 100% of the aldosterone stimulating activity of angiotensin II. Angiotensin IV has its own distinct receptor (AT$_4$) and has central nervous system effects together with some opposing actions to angiotensin II (von Bohlen und Halbach 2003). Enzymatic cleavage of the carboxy-terminus of angiotensin II or angiotensin I can produce the biologically active fragment angiotensin (1-7).

There has been renewed interest in the circulating RAS following the simultaneous discovery by two independent research groups in 2000 of an ACE homologue called ACE2. These two enzymes share 61% protein sequence similarity but have distinct enzymatic actions and tissue distributions (Donoghue et al 2000, Tipnis et al 2000). Like ACE, ACE2 is a zinc metalloprotease and a type I integral membrane protein expressed predominantly on the cell surface and as such acts as an ectoenzyme (Warner et al 2005). In its membrane bound form it comprises an extracellular N-terminal domain containing the active site and a short intracellular C-terminal anchor. The highest levels of ACE2 are seen in the kidney, heart, testis and gastrointestinal tract (particularly ileum, duodenum, jejunum, caecum and colon) with lower levels expressed in liver and lung (Harmer et al 2002, Hamming et al 2004, Donoghue 2000, Tipnis 2000). ACE2 can be released from the cell surface by the action of a secretase-like enzyme and the soluble ACE2 formed can be detected in plasma and urine (Lambert et al 2005, Lew et al 2006, Ocaranza et al 2006, Rice et al 2006). In contrast to ACE, ACE2 contains only a single catalytic domain compared with the two active sites (N- and C-domains) of somatic ACE. Furthermore, ACE2 is a carboxypeptidase rather than a peptidyl dipeptidase. As a consequence of its mechanism of action, ACE2 has different substrate specificity to that of ACE (Warner et al 2004) and also is not inhibited in-vitro by ACE inhibitors such as captopril, lisinopril or enalaprilat (Tipnis 2000).

ACE2 has activity on a number of biologically active peptides including angiotensin I and angiotensin II, des Arg$^9$ bradykinin, apellin 13 and dynorphin A (1-13) (Vickers et al 2002). The enzyme has a preference for hydrophobic or basic residues at the carboxy-terminus as well as for propyl residues at the penultimate position (Table 1) (Turner 2003).

The many diverse functions and interactions of ACE2 are only now being realised (Burrell et al 2004, Thomas and Tikellis 2005). This enzyme is not only crucial in cardiovascular and renal injury, but also has been identified as the receptor for the SARS coronavirus (W. Li et al 2003). Of particular interest over the past 5 years
Table 1. Peptide substrates for ACE2 showing catalytic efficiency in descending order. Note that ACE2 catalytic efficiency for angiotensin II is 400 fold that of angiotensin I (Vickers 2002)

| Substrate           | Site of cleavage | Catalytic efficiency ($k_{cat}/K_m$) |
|---------------------|------------------|--------------------------------------|
| Dynorphin A (1-13)  | L-K              | $3.1 \times 10^6$ m$^{-1}$s$^{-1}$    |
| Apelin-13           | P-F              | $2.1 \times 10^6$ m$^{-1}$s$^{-1}$    |
| **Angiotensin II**  | **P-F**          | **1.9 \times 10^6$ m$^{-1}$s$^{-1}$** |
| Des-Arg$^9$-bradykinin | P-F          | $1.3 \times 10^5$ m$^{-1}$s$^{-1}$    |
| **Angiotensin I**   | **H-L**          | **4.9 \times 10^5$ m$^{-1}$s$^{-1}$** |

has been the role of ACE2 in the formation of the biologically active fragment angiotensin (1-7). ACE2 can generate angiotensin (1-7) directly through enzymatic cleavage of angiotensin II or indirectly by cleaving angiotensin I into the inactive peptide fragment angiotensin (1-9), which is then further enzymatically cleaved by ACE to angiotensin (1-7) (Zisman et al 2003, Zisman et al 2003). Of these two pathways, the conversion of angiotensin II to angiotensin (1-7) by ACE2 is kinetically favoured in-vitro (Vickers 2002, Rice et al 2004). Furthermore, in-vitro studies show ACE2 to be 10- to 600-fold more potent in hydrolysing Angiotensin II to Angiotensin (1-7) than propyl endopeptidase and propyl carboxypeptidase, peptidases with similar carboxypeptidase actions (Ferrario 2003). These findings suggest that ACE2 is a major angiotensin (1-7) generating enzyme as well as an important enzyme for the degradation of angiotensin II.

The biological effects of angiotensin (1-7) were first described in the rat hypothalamic-hypophysial implant in 1988 in which angiotensin (1-7) stimulated release of vasopressin (Schiavone et al 1988). Subsequent animal experiments have shown angiotensin (1-7) to have antihypertensive (Benter et al 1995), antiarrhythmic (Ferreira, Santos and Almeida 2001) and cardioprotective properties (Ferreira, Santos and Almeida 2002). The vasodilatory effects of angiotensin (1-7) are mediated through the release of nitric oxide (NO) (Nakamoto et al 1995, P. Li et al 1997, Brosnihan, Li and Ferrario 1996), prostaglandins (Freeman et al 1996, Iyer et al 2000) and the release and interaction with bradykinin (P. Li 1997, Gorelik, Carbini and Scicli 1998, Fernandes et al 2001, Ueda et al 2001). Angiotensin (1-7) has also been shown to have anti-trophic properties in vascular endothelial, smooth muscle cells, cardiac myocytes, and cardiac fibroblasts (Freeman 1996, Strawn, Ferrario and Tallant 1999, Iwata et al 2005, Tallant, Ferrario and Gallagher 2005). In addition, anti-inflammatory, anti-fibrotic (Grobe et al 2006, Grobe et al 2006) and anti-thrombotic properties (Kucharewicz et al 2000, Kucharewicz et al 2002) have been attributed to angiotensin (1-7).

The putative receptor for angiotensin (1-7) is the G protein-coupled receptor encoded by the *Mas* proto-oncogene (Santos et al 2003). This receptor has been shown in-vitro to hetero-oligomerize with the AT$_1$ receptor and act as a physiological antagonist to angiotensin II as well as interact with the AT$_2$ receptor (Castro et al 2005, Kostenis et al 2005). Evidence is emerging that AT$_2$ receptors and other yet unidentified angiotensin (1-7) receptor subtypes may be important
in the biological action of angiotensin (1-7) (Walters, Gaspari and Widdop 2005, Silva et al 2006). Some of the actions of angiotensin (1-7) clearly oppose those of angiotensin II and consequently it has been proposed that the RAS can be divided on this basis into two distinct arms that are capable of producing complementary effects (Fig. 1). Thus our conceptual understanding of the RAS has evolved from an endocrine system consisting of a linear sequence of enzymatic reactions yielding the effector peptide angiotensin II to a complex system closely integrated with other systems (such as the kinin-kallikrein system) with the potential of producing effector peptides with counterbalancing effects (angiotensin (1-7) and angiotensin II). Importantly, the RAS is not just a systemic endocrine system but also can function autonomously as a paracrine system within certain organs.

3.2. The Intra-hepatic RAS

Local or intra-organ renin-angiotensin systems have been described in a number of organs including the heart, kidney, liver and pancreas (Bataller 2003, Leung and Chappell 2003). These local systems have been shown to be responsive to various stimuli of physiological and pathophysiological importance. Moreover, the locally generated angiotensin peptides fragments have a plethora of actions and have been

Figure 1. The Renin-Angiotensin System. Peptides are shown in blue boxes, enzymes in yellow boxes and target receptors in pink boxes. The system has four known biologically active peptides, angiotensin II, III, IV and angiotensin 1-7, which act through distinct cellular receptors (AT$_1$-4 and Mas). The two principal arms of this system act via the AT$_1$ and Mas receptors and have opposing actions.
implicated in cell growth, anti-proliferation, apoptosis, reactive oxygen species
generation, hormonal secretion, pro-inflammatory, and pro-fibrogenic actions.

The role of the hepatic RAS in normal and diseased liver is less well described
than that of the heart and kidney. However, it is clear that most of the key
components of the enzymatic cascade that lead to the formation of angiotensin
II in other organs are present in the liver. One common theme throughout the
literature is the observation that liver injury is associated with an up-regulation
and/or redistribution of RAS components including angiotensinogen, renin, ACE,
angiotensin II and AT\textsubscript{1} receptors (Sakata et al 1991, Paizis et al 2002, Bataller
2003). The main source of the RAS precursor, angiotensinogen, is the hepatocyte
(Morris, Iwamoto and Reid 1979, Paizis 2002), but low levels of protein have
also been detected in Kupffer cells, and in the bile duct epithelium (Sawa 1990).
Studies in humans and rodents show plasma renin concentration and activity
and its substrate angiotensinogen are increased in cirrhotic livers compared to
controls (Morris 1979, Richoux et al 1983, Kojima et al 1998, Rincon-Sanchez
et al 2005, Rivera-Huizar et al 2006). The product of angiotensiogen cleavage
by renin, angiotensin I, has not been demonstrated in liver tissue, however, there
is evidence to suggest de novo generation of angiotensin I may occur locally in
hepatomesenteric vascular beds as well as in circulating plasma (Admiraal et al
1990). In contrast, angiotensin II is present in both plasma and liver tissue from
normal animals and increases significantly in rat models of liver disease and
in cirrhotic patients (Asbert et al 1992, Wang et al 2003, Herath et al 2006).
Other RAS components expressed in the normal liver tissue include ACE and the
AT\textsubscript{1} receptor which are both predominantly localised to vascular endothelia, but
are also observed in hepatocytes and bile duct epithelial cells (H. S. Wei et al
2000, Ikura et al 2005). In the fibrotic liver, ACE and AT\textsubscript{1} protein expression is
also found in fibrous septa, mesenchymal cells (hepatic stellate cells and myofi-
broblasts) and Kupffer cells (H. S. Wei 2000, Paizis 2002, Leung et al 2003,
Ikura 2005).

Although the AT\textsubscript{1} receptor is abundant in the liver, the expression of the
AT\textsubscript{2} receptor gene is very low or not detectable in normal or diseased liver
(Paizis 2002, Bataller 2003, Nabeshima et al 2006). The only report so far to
attribute AT\textsubscript{2} receptor gene expression to a particular liver cell type is that
of Bataller and co-workers who detected low levels of the receptor messenger
RNA in isolated human hepatocytes and all HSC phenotypes (quiescent, culture
activated and in vivo activated) (Bataller 2003). Despite the possible existence
of AT\textsubscript{2} receptors in the liver, and a recent study showing that ablation of
AT\textsubscript{2} receptors augments liver injury and fibrosis (Nabeshima 2006), the vast
majority of reports support the concept that AT\textsubscript{1} receptors mediate most of the
inflammatory, proliferative and vascular effects of angiotensin II in the liver
(Bataller 2003, Kanno, Tazuma and Chayama 2003, Yoshiji et al 2003, Bataller
et al 2005). Moreover, the gene expression of AT\textsubscript{1} on human myofibroblasts has
been shown to correlate with the extent of fibrosis and degree of portal hypertension
(Ikura 2005).
4. HEPATIC FIBROSIS AND THE RAS

There is increasing evidence that in the liver, angiotensin II regulates cell growth and fibrosis and is involved in key events of inflammation and wound healing. One cell type that is pivotal in these processes is the activated hepatic stellate cell. Following injury, expression of AT$_1$ receptors is increased on activated hepatic stellate cells and these cells demonstrate increased responsiveness to angiotensin II compared to quiescent HSC (Bataller et al 2000). Incubation of the activated HSCs with angiotensin II results in a dose dependent increase in intracellular calcium concentration, cell contraction and cellular proliferation through a mitogen-activated protein kinase (MAPK) -dependent pathway and these effects are blocked by losartan, an angiotensin II type 1 receptor antagonist (ARB), (Bataller 2000). ARBs block other dose dependent profibrotic and proinflammatory effects of angiotensin II on HSCs including the expression of inflammatory cytokines and growth factors such as TGF-β1, IL-1β, CTGF, and NF-κβ, production of extracellular matrix (ECM) and fibrotic markers, smooth muscle α-actin and collagen (H. S. Wei 2000, Ohishi et al 2001, Yoshiji et al 2001, Bataller 2003, Kurikawa et al 2003, Y. Zhang et al 2003, Y. J. Zhang et al 2003). Angiotensin II is also a powerful chemo-attractant for activated HSCs concentrating these cells at the site of hepatic injury (Bataller et al 2003). These effects may be amplified by upregulation of key components of a local RAS by liver injury (Paizis 2002, Bataller 2003), creating an autocrine loop in which liver injury increases angiotensin II production and this in turn perpetuates liver damage and fibrosis.

A recent study showed that these profibrogenic effects of angiotensin II in human hepatic stellate cells are at least in part mediated via the generation of reactive oxygen species (ROS) by NADPH oxidase. This proposed mechanism is supported by the finding that hepatic fibrosis following bile duct ligation is markedly attenuated in NADPH oxidase-deficient mice (Bataller 2003). NADPH oxidase is expressed in other hepatic cell types including Kupffer cells and sinusoidal endothelial cells and these cells may also contribute to fibrogenesis through the formation of ROS (Whalen et al 1999, Kono et al 2000).

The importance of the RAS in hepatic fibrosis is supported by studies which have shown that inflammation and fibrosis in response to both CCL4 treatment (Kanno 2003) and bile duct ligation (Yang et al 2005) are attenuated in AT$_1$ knockout mice. Supporting evidence has also come from in-vivo studies which have shown that angiotensin II infusion stimulates proliferation of bile duct cells, exacerbates liver fibrosis and increases serum transaminases and endotoxin levels in BDL rat livers (Bataller et al 2005). Interestingly, angiotensin II infusion increases the number of vascular thromboses of small hepatic vessels within portal tracts in both BDL and sham operated animals, the putative mechanism being an increase in tissue factor procoagulant activity (Bataller 2005). This prothrombotic effect of angiotensin II may contribute to further liver injury and collagen deposition by causing local hypoxia (Corpechot et al 2002).

In addition to its direct profibrotic effects, angiotensin II is an amplifier of the general inflammatory response to chronic liver injury and induces acute phase
reactants, oxidative stress, the release of inflammatory and fibrogenic cytokines (IL-6, IL-1, TGFβ1, TNFα) and ECM deposition (Bataller 2003, Miyoshi et al 2003, Bataller 2005, Sasaki et al 2005). In addition to complex interactions with other cell types, angiotensin II induces the secretion of monocyte chemoattractant protein (MCP-1) and IL-8 from activated HSCs (Marra et al 1998, Kanno et al 2005). MCP-1 is a low molecular weight secretory protein that potently stimulates leukocyte recruitment and activation. Upregulation of MCP-1 gene expression is thought to be mediated via Rho intracellular signalling pathways following angiotensin II binding to the AT1 receptor (Kanno 2005). Other events that occur as a result of AT1 receptor activation include the release of a number of transcription factors; activator Protein 1 (AP-1), signal transducer and activator of Transcription (STATs) and NFκB (Jamaluddin et al 2000, McAllister-Lucas et al 2006), which are crucial for many of the downstream pro-inflammatory effects of angiotensin II such as the production of cytokine, IL-6. Furthermore, activation of the transcription factor NFκB is a fundamental positive feedback mechanism by which angiotensin II acting at AT1 receptors located on hepatocytes stimulates the transcription of angiotensinogen, the precursor of angiotensin (Ron, Brasier and Habener 1990, Brasier, Li and Copland 1994). A number of cell types present within the liver express AT1 receptors and may contribute to these proinflammatory effects of AngII (Leung 2003, X. Zhang et al 2004). For example, Kupffer cells, the resident hepatic macrophage, are activated in alcoholic liver disease and are stimulated by angiotensin II to produce TNF-α and TGF-β1 (Enomoto et al 2000). The production of these cytokines by Kupffer cells is significantly reduced by the angiotensin receptor antagonist (ARB), losartan but not the ACE inhibitor captopril, confirming the role of the AT1 receptor in this cell type (Y. H. Wei, Jun and Qiang 2004).

The hepatic RAS also appears to affect the balance between ECM deposition and degradation which depends on the relative activity of matrix metalloproteinases (MMPs) and their inhibitors, tissue inhibitors of metalloproteinases (TIMPs). TIMP-1 is a broad specificity inhibitor of MMPs which acts by forming 1:1 complexes with MMPs. Angiotensin II upregulates TIMP-1 mRNA expression in activated HSCs through AT1 receptor binding and subsequent protein kinase C (PKC) intracellular signalling pathways. This has been verified in two animal models of fibrosis (pig serum and CCL4) where down-regulation of TIMP-1 gene expression followed administration of ACE inhibitors or ARB (Yoshiji 2003).

Paizis et al, recently demonstrated that ACE2 gene expression and protein levels are markedly elevated in the BDL liver and cirrhotic human liver tissue, opening the possibility that this putative counter-regulatory arm of the RAS is actively involved in chronic liver disease (Paizis et al 2005). In addition angiotensin (1-7), ACE2 and Mas, have recently been shown to increase progressively following bile duct ligation in rats (Herath 2006, Lubel et al 2006, Pereira et al 2006). Furthermore in this same model, pharmacological blockade of the Mas receptor may worsen liver fibrosis (Pereira 2006). The potential benefits of angiotensin (1-7) are of particular clinical relevance because both ACE inhibitors and angiotensin receptor blockers (ARBs) can result in elevations in angiotensin (1-7) raising the possibility that some
of the beneficial effects of these drugs are mediated by this peptide (Iyer, Ferrario and Chappell 1998, Collister and Hendel 2003).

4.1. Effects of RAS Inhibition on Hepatic Fibrosis in vivo

ACE inhibitors have been found to have multiple benefits in both cardiovascular and renal disease (hypertension, prevention of myocardial infarction and stroke, preventing heart failure, arrhythmias, renal failure, proteinuria and diabetic nephropathy). Losartan was the first drug of an alternative class of RAS antagonists which block the angiotensin II type 1 receptor. Subsequently a large number of ACE inhibitors and angiotensin receptor blockers (ARBs) have been developed. These two classes of drug collectively have been shown to reduce chronic end-organ damage in cardiovascular and renal disease and diabetes. The benefits of these drugs appear to be independent of their antihypertensive effects suggesting that they have direct antifibrotic or tissue protective effects in these diseases.

4.2. Studies in Animal Models

Interventional animal studies using RAS inhibitors have provided compelling evidence that the RAS plays a major role in the pathogenesis of hepatic fibrosis. Most of these studies have been performed in rodents and several established models of hepatic fibrosis have been used (Table 2) (Ramos et al 1994, H. Wei et al 2000, Jonsson et al 2001, Ohishi 2001, Paizis et al 2001, Yoshiji et al 2001, Croquet et al 2002, Ramalho et al 2002, Toblli et al 2002, Yoshiji et al 2002, Kurikawa 2003, X. Li et al 2003, Tuncer et al 2003, Yoshiji 2003, Y. H. Wei 2004, Yoshiji et al 2005). Although methodologies have differed widely, there is a surprising degree of uniformity in the results. In almost all published studies, both ACE inhibitors and AT1 receptor blockers have been shown to have beneficial effects. These include both the attenuation of fibrosis and down-regulation of key inflammatory and profibrotic cytokines known to be involved in the pathogenesis of hepatic fibrosis. A summary of the major findings of these studies is provided in Table 2.

One of the most common and serious complications of cirrhosis is the development of hepatocellular carcinoma. In keeping with the known proliferative and angiogenic effects of angiotensin II, there is increasing evidence that the RAS is involved in the development and growth of this neoplasm. Experiments in mice have shown that the potent angiogenic factor vascular endothelial growth factor (VEGF) is induced by angiotensin II and that the ACE inhibitor, perindopril, significantly attenuates VEGF-mediated tumour development. (Yoshiji, Kuriyama and Fukui 2002, Yoshiji et al 2002)

4.3. Human Studies

The efficacy, ease of use and excellent safety profile of RAS blockers in the treatment of patients with cardiovascular and renal disease makes them an attractive


| Model                      | Strain/Species | RAS Blocker       | Histological improvement | OH Proline | Fibrosis markers | Collagen expression | Portal pressure/flow | TGFB | MMP | PDGF | α-SMA | Author                  |
|----------------------------|----------------|------------------|--------------------------|------------|-----------------|----------------------|----------------------|------|-----|------|------|-------------------------|
| Bile Duct Ligation (BDL)   | SD Rat         | Losartan         | ✓ ✓ ×                    |            |                 |                      |                      | ✓    |     |      |      | (Croquet et al. 2002)   |
|                            | Lewis Rats     | Captopril        | ✓ ✓ ✓                    | ✓          |                 | ✓                    | ✓                    |       |     |      |      | (Jonsson et al. 2001)   |
|                            | SD Rat         | Olmesartan       | ✓ ✓ ✓                    | ✓          |                 | ✓                    | ✓                    |       |     |      |      | (Kurikawa et al. 2003)  |
|                            | SD Rat         | Irbesartan       | × × ✓                    | ✓          |                 | ✓                    | ✓                    |       |     |      |      | (Paizis et al. 2001)    |
|                            | Wistar Rat     | Losartan         | ✓ ✓ ✓ ✓                  |            |                 | ✓                    | ✓                    | ✓    |     |      | ✓    | (Ramalho et al. 2002)   |
| Carbon Tetrachloride (CCL₄)| SD Rat         | Losartan         | ✓ ✓ ✓ ✓                  |            |                 | ✓                    | ✓                    | ✓    |     |      | ✓    | (Croquet et al. 2002)   |
|                            | Wistar Rat     | Perindopril      | ✓ ✓ ✓ ✓ ✓ ✓ ✓            |            |                 | ✓                    | ✓                    |       |     |      |      | (X. Li et al. 2003)     |
|                            | Wistar Rat     | Losartan         | ✓ ✓ ✓ ✓ ✓ ✓ ✓            |            |                 | ✓                    | ✓                    |       |     |      |      | (X. Li et al. 2003)     |
|                            | Wistar Rat     | Perindopril      | ✓ ✓ ✓ ✓ ✓ ✓ ✓            |            |                 | ✓                    | ✓                    |       |     |      |      | (X. Li et al. 2004)     |
|                            | SD Rat         | Lisinopril       | ✓ ✓ ✓ ✓                  |            |                 | ✓                    | ✓                    | ✓    |     |      | ✓    | (Ohishi et al. 2001)    |
|                            | SD Rat         | Captopril        | × ✓ ✓ ✓                  |            |                 | ✓                    | ✓                    |       |     |      | ✓    | (Tuncer et al. 2003)    |
|                            | Candesartan    |                 | ✓                        |            |                 |                      |                      | ✓    |     |      | ✓    | (H. S. Wei et al. 2000) |
|                            | SD Rat         | Losartan         | ✓ ✓ ✓ ✓                  |            |                 | ✓                    | ✓                    | ✓    |     |      | ✓    | (Y. H. Wei et al. 2004) |
|                            | Losartan & Enalapril |              | ✓ ✓ ✓ ✓                  |            |                 | ✓                    | ✓                    | ✓    |     |      | ✓    |                        |
|                            | Fisher Rats    | Candesartan      | ✓                        |            |                 |                      |                      | ✓    |     |      | ✓    | (Yoshiji et al. 2003)   |
|                            | Perindopril    |                 | ✓                        |            |                 |                      |                      | ✓    |     |      | ✓    | (Yoshiji et al. 2005)   |
|                            | BALB/c mice    | Perindopril      | ✓ ✓ ✓ ✓ ✓ ✓ ✓            |            |                 | ✓                    | ✓                    | ✓    |     |      |      | (Yoshiji et al. 2005)   |
| Condition                                      | Animal   | Drug     | ✓    | ✓    | ✓    | ✓    | Reference                  |
|------------------------------------------------|----------|----------|------|------|------|------|---------------------------|
| Portal Vein Ligation (PVL)                     | SD Rat   | Losartan | ✗    | ✗    | ✗    | ✗    | (Croquet et al. 2002)     |
| Adriamycin induced nephrotic syndrome          | SD Rat   | Enalapril| ✓    | ✓    | ✓    | ✗    | (Toblli et al. 2002)      |
| Choline deficient L-amino aci12fd (CDAA) diet  | Fisher Rat| Perindopril | ✓    | ✓    | ✓    | ✓    | (Yoshiji et al. 2002)     |
| Pig serum injection                            | Wistar Rat| Captopril | ✓    | ✓    | ✓    | ✓    | (Ramos et al. 1994)       |
|                                               | Fisher Rats| Candesartan | ✓    | ✓    | ✓    | ✓    | (Yoshiji et al. 2001)     |
|                                               | Fisher Rats| Perindopril | ✓    | ✓    | ✓    | ✓    | (Yoshiji et al. 2003)     |

SD, Sprague Dawley; OH Proline, hydroxyproline; ✓ denotes a positive finding; ✗ denotes a negative finding.
potential therapy for the treatment of human liver disease. The effects of AT\textsubscript{1} blockade on portal hypertension have been examined in a number of studies. The rationale for these studies is that angiotensin II increases intra hepatic resistance to portal flow in the cirrhotic liver by mediating contraction of perisinusoidal myofibroblasts and thus contributes to the variable component of portal hypertension (Vlachogiannakos et al 2001). Although some studies have shown that these drugs can lower portal pressure, their use has been associated with unacceptable drops in systemic blood pressure and renal blood flow, particularly in patients with advanced liver disease. This is because the systemic renin angiotensin system is activated in such patients in response to systemic and mesenteric vasodilation (Arroyo et al 1979, Bosch et al 1980, Sakata 1991) and plays a central role in the maintenance of renal perfusion pressure and glomerular filtration.

There have been only a small number of studies examining the effects of RAS inhibition on fibrosis in human liver disease and there are no large randomised trials. This may at first seem surprising considering the wealth of supportive evidence that has come from animal and in-vitro studies. However, studies of antifibrogenic therapies are difficult to perform in man because of the need to perform multiple biopsies. In addition, fibrosis progresses very slowly in most common diseases such as hepatitis C and non-alcoholic fatty liver disease making it difficult to detect possible beneficial effects of antifibrotic therapy unless studies are conducted over a number of years.

One small study (n=7) found that administration of the angiotensin II receptor antagonist losartan 50mg/day for 48 weeks in patients with non-alcoholic steatohepatitis (NASH) reduced serum TGF-β, ferritin and aminotransferases. Five patients showed improvement in the grade of hepatic necro-inflammation. Importantly, this small study had no control group and was not analysed on an intention to treat basis (Yokohama et al 2004). In a subsequent study the pre and post treatment biopsies of seven patients with non-alcoholic steato-hepatitis treated with losartan (50mg/day for 48 weeks) were compared with eight patients with non-alcoholic fatty liver disease who acted as a control group. The treatment group showed a significant improvement in necro-inflammatory grade, stage of fibrosis, significantly fewer activated HSCs and a mild increase in quiescent HSCs (Yokohama et al 2006) at the end of 48-weeks. However, the lack of a proper randomised control group is a particular problem in studies of patients with NASH since the disease can improve in response to changes in life style.

A number of studies have reported possible antifibrotic effects of RAS blockers in patients with hepatitis C. In one study, 30 HCV infected patients with mild fibrosis were treated with losartan 50mg/day and ursodeoxycholic acid 600mg/day whilst controls received ursodeoxycholic acid alone. There were significant differences in serum markers of hepatic fibrosis (TGF-β1 and type IV collagen) in the losartan and ursodeoxycholic acid group, but no significant changes in fibrosis score (METAVIR scoring system) were observed. The full details of this study have not been published (Rimola et al 2004). Another report published in letterform only described outcomes in patients with hepatitis C treated with low-dose interferon
(IFN alpha 3x10⁶ IU 3 times a week for 12 months) in combination with the ACE inhibitor, perindopril (4mg/day). Treatment was accompanied by significant improvement in serum markers of fibrosis (hyaluronic acid, type IV collagen 7S and procollagen III-N-peptide), however, histological analysis was not performed. Unfortunately, it is impossible to determine from this study whether any of the observed effects were due to perindopril itself as a perindopril monotherapy group was not included (Yoshiji, Noguchi and Fukui 2005). Finally, a retrospective review which compared liver histology in liver transplant patients with recurrent hepatitis C who were taking RAS blocking drugs (n=27) with those who were not (n=101) showed that the group taking RAS blockers were less likely to develop severe hepatic fibrosis (bridging fibrosis or cirrhosis) at 1 and 10 years post transplantation compared to the control group (15% vs. 35% at 1 year (P<0.05), and 35% vs. 70% at 10 years (P<0.005), respectively) (Rimola 2004).

5. CONCLUSIONS

Recent studies have provided clear evidence that there is an hepatic RAS that may be of major importance in the pathogenesis of chronic liver disease. This system is upregulated by chronic liver injury and contributes to oxidative stress, recruitment of inflammatory cells and the development of fibrosis. The RAS also plays a role in the pathogenesis of portal hypertension and many of the systemic complications of cirrhosis. There is ample evidence from in-vitro studies and work in a number of animal models of liver disease to suggest that blockade of the RAS can ameliorate liver injury, inhibit hepatic fibrosis and lower portal pressure. Whilst ACE inhibitors and ARB have proven to be invaluable pharmacological tools, most studies have employed higher doses of these drugs than are used clinically. It remains to be determined whether RAS inhibition will prove to be an effective therapeutic approach for the treatment and prevention of hepatic fibrosis and its complications in human liver disease.

ACKNOWLEDGEMENTS

J.S. Lubel is the recipient of an Australian Postgraduate National Health and Medical Research Council (NHMRC) Scholarship and F.J. Warner is supported by a Rolf Edgar Lake Fellowship. This work was facilitated by funding from the NHMRC (Australia).

REFERENCES

Admiraal PJ, Derkx FH, Danser AH, Pieterman H and Schalekamp MA 1990 Metabolism and production of angiotensin I in different vascular beds in subjects with hypertension *Hypertension* 15 1 44–55

Ardaillou R 1997 Active fragments of angiotensin II: enzymatic pathways of synthesis and biological effects *Curr Opin Nephrol Hypertens* 6 1 28–34

Arroyo V, Bosch J, Mauri M, Viver J, Mas A, Rivera F and Rodes J 1979 Renin, aldosterone and renal haemodynamics in cirrhosis with ascites *Eur J Clin Invest* 9 1 69–73
Arthur MJ 2000 Fibrogenesis II. Metalloproteinases and their inhibitors in liver fibrosis *Am J Physiol Gastrointest Liver Physiol* 279 2 G245–9

Asbert M, Jimenez W, Gayà J, Gines P, Arroyo V, Rivera F and Rodes J 1992 Assessment of the renin-angiotensin system in cirrhotic patients. Comparison between plasma renin activity and direct measurement of immunoreactive renin *J Hepatol* 15 1-2 179–83

Basso N and Terragno NA 2001 History about the discovery of the renin-angiotensin system *Hypertension* 38 6 1246–9

Bataller R, Gabele E, Parsons CJ, Morris T, Yang L, Schoonhoven R, Brenner DA and Rippe RA 2005 Systemic infusion of angiotensin II exacerbates liver fibrosis in bile duct-ligated rats *Hepatology* 41 5 1046–55

Bataller R, Gines P, Nicolas JM, Gorbig MN, Garcia-Ramallo E, Gasull X, Bosch J, Arroyo V and Rodes J 2000 Angiotensin II induces contraction and proliferation of human hepatic stellate cells *Gastroenterology* 118 6 1149–56

Bataller R, Sancho-Bru P, Gines P and Brenner DA 2005 Liver fibrogenesis: a new role for the renin-angiotensin system *Antioxid Redox Signal* 7 9-10 1346–55

Bataller R, Sancho-Bru P, Gines P, Lora JM, Al-Garawi A, Sole M, Colmenero J, Nicolas JM, Jimenez W, Weich N, Gutierrez-Ramos JC, Arroyo V and Rodes J 2003 Activated human hepatic stellate cells express the renin-angiotensin system and synthesize angiotensin II *Gastroenterology* 125 1 117–25

Bosch J, Arroyo V, Betriu A, Mas A, Carrilho F, Riverà F, Navarro-Lopez F and Rodes J 1980 Hepatic hemodynamics and the renin-angiotensin-aldosterone system in cirrhosis *Gastroenterology* 78 1 92–9

Brasier AR, Li J and Copland A 1994 Transcription factors modulating angiotensinogen gene expression in hepatocytes *Kidney Int* 46 6 1564–6

Brosnihan KB, Li P and Ferrario CM 1996 Angiotensin-(1-7) dilates canine coronary arteries through kinins and nitric oxide *Hypertension* 27 3 Pt 2 523–8

Burrell LM, Johnston CI, Tikellis C and Cooper ME 2004 ACE2, a new regulator of the renin-angiotensin system *Trends Endocrinol Metab* 15 4 166–9

Cassiman D and Roskams T 2002 Beauty is in the eye of the beholder: emerging concepts and pitfalls in hepatic stellate cell research *J Hepatol* 37 4 527–35

Castro CH, Santos RA, Ferreira AJ, Bader M, Alenina N and Almeida AP 2005 Evidence for a functional interaction of the angiotensin-(1-7) receptor Mas with AT1 and AT2 receptors in the mouse heart *Hypertension* 46 4 937–42

Collister JP and Hendel MD 2003 The role of Ang (1-7) in mediating the chronic hypotensive effects of losartan in normal rats *J Renin Angiotensin Aldosterone Syst* 4 3 137–9

Corpechot C, Barbu V, Wendum D, Kimmian N, Rey C, Poupon R, Housset C and Rosmorduc O 2002 Hypoxia-induced VEGF and collagen I expressions are associated with angiogenesis and fibrogenesis in experimental cirrhosis *Hepatology* 35 5 1010–21

Croquet V, Moal F, Veal N, Wang J, Oberti F, Roux J, Vuillemín E, Gallois Y, Douay Y, Chappard D and Cales P 2002 Hemodynamic and antifibrotic effects of losartan in rats with liver fibrosis and/or portal hypertension *J Hepatol* 37 6 773–80

Donoghue M, Hsieh F, Baronas E, Godbout K, Gosselin M, Stagliano N, Donovan M, Woolf B, Robison K, Jeyaseelan R, Breithart RE and Acton S 2000 A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9 *Circ Res* 87 5 E1–9

Enomoto N, Ikejima K, Bradford BU, Rivera CA, Kono H, Goto M, Yamashina S, Schemmer P, Kitamura T, Oide H, Takei Y, Hirose M, Shimizu H, Miyazaki A, Brenner DA, Sato N and Thurman RG 2000 Role of Kupffer cells and gut-derived endotoxins in alcoholic liver injury *J Gastroenterol Hepatol* 15 Suppl D20–5
THE ROLE OF THE RENIN-ANGIOTENSIN SYSTEM IN HEPATIC FIBROSIS

Fernandes L, Fortes ZB, Nigro D, Tostes RC, Santos RA and Catelli De Carvalho MH 2001 Potentiation of bradykinin by angiotensin-(1-7) on arterioles of spontaneously hypertensive rats studied in vivo Hypertension 37 2 Part 2 703–9

Ferrario CM 2003 Commentary on Tikellis et al: There is more to discover about angiotensin-converting enzyme Hypertension 41 3 390–1

Ferreira AJ, Santos RA and Almeida AP 2001 Angiotensin-(1-7): cardioprotective effect in myocardial ischemia/reperfusion Hypertension 38 3 Pt 2 665–8

Ferreira AJ, Santos RA and Almeida AP 2002 Angiotensin-(1-7) improves the post-ischemic function in isolated perfused rat hearts Braz J Med Biol Res 35 9 1083–90

Freeman EJ, Chisolm GM, Ferrario CM and Tallant EA 1996 Angiotensin-(1-7) inhibits vascular smooth muscle cell growth Hypertension 28 1 104–8

Friedman SL, Maher JJ and Bissell DM 2000 Mechanisms and therapy of hepatic fibrosis: report of the AASLD Single Topic Basic Research Conference Hepatology 32 6 1403–8

Gorelik G, Carbini LA and Scicli AG 1998 Angiotensin 1-7 induces bradykinin-mediated relaxation in porcine coronary artery J Pharmacol Exp Ther 286 1 403–10

Grobe JL, Mecca AP, Lingis M, Shenoy V, Bolton TA, Machado JM, Speth RC, Raizada MK and Katovich M 2006 Prevention of Angiotensin II-Induced Cardiac Remodeling by Angiotensin-(1-7) Am J Physiol Heart Circ Physiol

Grobe JL, Mecca AP, Mao H and Katovich MJ 2006 Chronic angiotensin-(1-7) prevents cardiac fibrosis in DOCA-salt model of hypertension Am J Physiol Heart Circ Physiol 290 6 H2417–23

Hamming I, Timens W, Bulthuis ML, Lely AT, Navis GJ and van Goor H 2004 Tissue distribution of ACE 2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis J Pathol 203 2 631–7

Harmer D, Gilbert M, Borman R and Clark KL 2002 Quantitative mRNA expression profiling of ACE 2, a novel homologue of angiotensin converting enzyme FEBS Lett 532 1-2 107–10

Herath CB, Warner FJ, Lubel JS, Dean R, Lew RA, Smith AI, Burrell LM and Angus PW 2006 The balance between hepatic ACE2 and ACE determines plasma levels of vasodilator peptide angiotensin (1-7) in experimental biliary fibrosis Journal of Gastroenterology and Hepatology 21 Suppl. 4 A325

Ikura Y, Ohsawa M, Shirai N, Sugama Y, Fukushima H, Suekane T, Hirayama M, Ehara S, Naruko T and Ueda M 2005 Expression of angiotensin II type 1 receptor in human cirrhotic livers: Its relation to fibrosis and portal hypertension Hepatol Res 32 2 107–16

Iwata M, Cowling RT, Gurantz D, Moore C, Zhang S, Yuan JX and Greenberg BH 2005 Angiotensin-(1-7) binds to specific receptors on cardiac fibroblasts to initiate antifibrotic and antitrophic effects Am J Physiol Heart Circ Physiol 289 6 H2356–63

Iyer SN, Ferrario CM and Chappell MC 1998 Angiotensin-(1-7) contributes to the antihypertensive effects of blockade of the renin-angiotensin system Hypertension 31 1 Pt 2 356–61

Iyer SN, Yamada K, Diz DI, Ferrario CM and Chappell MC 2000 Evidence that prostaglandins mediate the antihypertensive actions of angiotensin-(1-7) during chronic blockade of the renin-angiotensin system J Cardiovasc Pharmacol 36 1 109–17

Jamaluddin M, Meng T, Sun J, Boldogh I, Han Y and Brasier AR 2000 Angiotensin II induces nuclear factor (NF)-kappaB1 isoforms to bind the angiotensinogen gene acute-phase response element: a stimulus-specific pathway for NF-kappaB activation Mol Endocrinol 14 1 99–113

Jonsson JR, Clouston AD, Ando Y, Kelemen LI, Horn MJ, Adamson DM, Purdie DM and Powell EE 2001 Angiotensin-converting enzyme inhibition attenuates the progression of rat hepatic fibrosis Gastroenterology 121 1 148–55

Kallis Y, Alison MR and Forbes SJ 2006 Bone marrow stem cells and liver disease Gut

Kanno K, Tazuma S and Chayama K 2003 AT1A-deficient mice show less severe progression of liver fibrosis induced by CCI(4) Biochem Biophys Res Commun 308 1 177–83

Kanno K, Tazuma S, Nishioka T, Hyogo H and Chayama K 2005 Angiotensin II participates in hepatic inflammation and fibrosis through MCP-1 expression Dig Dis Sci 50 5 942–8

Knittel T, Mehde M, Kobold D, Saile B, Dinter C and Ramadori G 1999 Expression patterns of matrix metalloproteinases and their inhibitors in parenchymal and non-parenchymal cells of rat liver: regulation by TNF-alpha and TGF-beta1 J Hepatol 30 1 48–60
Kojima H, Tsujimoto T, Uemura M, Takaya A, Okamoto S, Ueda S, Nishio K, Miyamoto S, Kubo A, Minamino N, Kangawa K, Matsuo H and Fukui H 1998 Significance of increased plasma adrenomedullin concentration in patients with cirrhosis J Hepatol 28 5 840–6
Kono H, Rusyn I, Yin M, Gabele E, Yamashina E, Dikalova A, Kadiiska MB, Connor HD, Mason RP, Segal BH, Bradford BU, Holland SM and Thurman RG 2000 NADPH oxidase-derived free radicals are key oxidants in alcohol-induced liver disease J Clin Invest 106 7 867–72
Kostenis E, Milligan G, Christopoulos A, Sanchez-Ferrer CF, Heringer-Walther S, Sexton PM, Gembardt F, Kellett E, Martini L, Vanderheiden P, Schultheiss HP and Walther T 2005 G-protein-coupled receptor Mas is a physiological antagonist of the angiotensin II type 1 receptor Circulation 111 14 1806–13
Kucharewicz I, Chabielska E, Pawlak D, Matys T, Rolkowski R and Buczko W 2000 The antithrombotic effect of angiotensin-(1-7) closely resembles that of losartan J Renin Angiotensin Aldosterone Syst 1 3 268–72
Kucharewicz I, Pawlak R, Matys T, Pawlak D and Buczko W 2002 Antithrombotic effect of captopril and losartan is mediated by angiotensin-(1-7) Hypertension 40 5 774–9
Kurikawa N, Suga M, Kuroda S, Yamada K and Ishikawa H 2003 An angiotensin II type 1 receptor antagonist, olmesartan medoxomil, improves experimental liver fibrosis by suppression of proliferation and collagen synthesis in activated hepatic stellate cells Br J Pharmacol 139 6 1085–94
Lambert DW, Yarski M, Warner FJ, Thornhill P, Parkin ET, Smith AI, Hooper NM and Turner AJ 2005 Tumor necrosis factor-alpha convertase (ADAM17) mediates regulated ectodomain shedding of the severe-acute respiratory syndrome-coronavirus (SARS-CoV) receptor, angiotensin-converting enzyme-2 (ACE2) J Biol Chem 280 34 30113–9
Leung PS and Chappell MC 2003 A local pancreatic renin-angiotensin system: endocrine and exocrine roles Int J Biochem Cell Biol 35 6 838–46
Leung PS, Suen PM, Ip SP, Yip CK, Chen G and Lai PB 2003 Expression and localization of AT1 receptors in hepatic Kupffer cells: its potential role in regulating a fibrogenic response Regul Pept 116 1-3 61–9
Lew RA, Warner FJ, Hanchapola I and Smith AI 2006 Characterization of angiotensin converting enzyme-2 (ACE2) in human urine International Journal Of Peptide Research And Therapeutics 12 3 283–289
Li P, Chappell MC, Ferrario CM and Brosnihan KB 1997 Angiotensin-(1-7) augments bradykinin-induced vasodilation by competing with ACE and releasing nitric oxide Hypertension 29 1 Pt 2 394–400
Li W, Moore MJ, Vasilieva N, Sui J, Wong SK, Berne MA, Somasundaran M, Sullivan JL, Luzuriaga K, Greenough TC, Choe H and Farzan M 2003 Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus Nature 426 6965 450–4
Li X, Meng Y, Yang XS, Zhang ZS, Wu PS and Zou JI 2004 [Perindopril attenuates the progression of CCl4-inducing rat hepatic fibrosis] Zhonghua Gan Zang Bing Za Zhi 12 1 32–4
Li X, Meng Y, Zhang ZS, Yang XS and Wu PS 2003 [Effect of ACE-I and AT-1 receptor blocker on the progression of CCl(4)-inducing rat hepatic fibrogenesis] Zhonghua Yi Xue Za Zhi 83 14 1241–5
Lodato F, Mazzella G, Festi D, Azzaroli F, Colecchia A and Roda E 2006 Hepatocellular carcinoma prevention: A worldwide emergence between the opulence of developed countries and the economic constraints of developing nations World J Gastroenterol 12 45 7239–49
Lubel JS, Herath CB, Warner FJ, Jia ZY, Burrell LM and Angus PW 2006 Upregulation of the ACE2/Ang(1-7)/Mas receptor axis in the bile duct ligation (BDL) model of hepatic fibrosis does not affect hepatic sinusoidal resistance Journal of Gastroenterology and Hepatology 21 Suppl 4 A332
Marra F, DeFranco R, Grappone C, Milani S, Pastacaldi S, Pinzani M, Romanelli RG, Laffi G and Gentilini P 1998 Increased expression of monocyte chemotactic protein-1 during active hepatic fibrogenesis: correlation with monocyte infiltration Am J Pathol 152 4 423–30
McAllister-Lucas LM, Ruland J, Siu K, Jin X, Gu S, Kim DS, Kuffa P, Kohrt D, Mak TW, Nunez G and Lucas PC 2006 CARMA3/Bcl10/MALT1-dependent NF-κB activation mediates angiotensin II-responsive inflammatory signaling in nonimmune cells Proc Natl Acad Sci U S A
THE ROLE OF THE RENIN-ANGIOTENSIN SYSTEM IN HEPATIC FIBROSIS

Miyoshi M, Nagata K, Imoto T, Goto O, Ishida A and Watanabe T 2003 ANG II is involved in the LPS-induced production of proinflammatory cytokines in dehydrated rats Am J Physiol Regul Integr Comp Physiol 284 4 R1092–7

Morris BJ, Iwamoto HS and Reid IA 1979 Localization of angiotensinogen in rat liver by immunocytochemistry Endocrinology 105 5 796–800

Nabeshima Y, Tazuma S, Kanno K, Hyogo H, Iwai M, Horiuchi M and Chayama K 2006 Anti-fibrogenic function of angiotensin II type 2 receptor in CCl4-induced liver fibrosis Biochem Biophys Res Commun 346 3 658–64

Nakamoto H, Ferrario CM, Fuller SB, Robaczewski DL, Winicov E and Dean RH 1995 Angiotensin-(1-7) and nitric oxide interaction in renovascular hypertension Hypertension 25 4 Pt 2 796–802

Ocaranza MP, Godoy I, Jalil JE, Varas M, Collantes P, Pinto M, Roman M, Ramirez C, Copaja M, Diaz-Araya G, Castro P and Lavandero S 2006 Enalapril attenuates downregulation of Angiotensin-converting enzyme 2 in the late phase of ventricular dysfunction in myocardial infarcted rat Hyper tension 48 4 572–8

Ohishi T, Saito H, Tsusaka K, Toda K, Inagaki H, Hamada Y, Kumagai N, Atsukawa K and Ishii H 2001 Anti-fibrogenic effect of an angiotensin converting enzyme inhibitor on chronic carbon tetrachloride-induced hepatic fibrosis in rats Hepatol Res 21 2 147–158

Paizis G, Cooper ME, Schembri JM, Tikellis C, Burrell LM and Angus PW 2002 Up-regulation of components of the renin-angiotensin system in the bile duct-ligated rat liver Gastroenterology 123 5 1667–76

Paizis G, Gilbert RE, Cooper ME, Murthi P, Schembri JM, Wu LL, Rumble JR, Kelly DJ, Tikellis C, Cox A, Smallwood RA and Angus PW 2001 Effect of angiotensin II type 1 receptor blockade on experimental hepatic fibrogenesis J Hepatol 35 3 376–85

Paizis G, Tikellis C, Cooper ME, Schembri JM, Lew RA, Smith AI, Shaw T, Warner FJ, Zulli A, Burrell LM and Angus PW 2005 Chronic liver injury in rats and humans upregulates the novel enzyme angiotensin converting enzyme 2 Gut 54 12 1790–6

Pereira RM, Dos Santos RA, Teixeira MM, Leite VH, Costa LP, da Costa Dias FL, Barcelos LS, Collares GB and Simoes ESAC 2006 The renin-angiotensin system in a rat model of hepatic fibrosis: Evidence for a protective role of Angiotensin-(1-7) J Hepatol

Ramalho LN, Ramalho FS, Zucoloto S, Castro-e-Silva Junior O, Correa FM, Elias Junior J and Magalhaes JP 2002 Effect of losartan, an angiotensin II antagonist, on secondary biliary cirrhosis Hepatogastroenterology 49 48 1499–502

Ramos SG, Montenegro AP, Goissis G and Rossi MA 1994 Captopril reduces collagen and mast cell and eosinophil accumulation in pig serum-induced rat liver fibrosis Pathol Int 44 9 655–61

Rice GI, Jones AL, Grant PJ, Carter AM, Turner AJ and Hooper NM 2006 Circulating activities of angiotensin-converting enzyme, its homolog, angiotensin-converting enzyme 2, and neprilysin in a family study Hypertension 48 5 914–20

Rice GI, Thomas DA, Grant PJ, Turner AJ and Hooper NM 2004 Evaluation of angiotensin-converting enzyme (ACE), its homologue ACE2 and neprilysin in angiotensin peptide metabolism Biochem J 383 Pt 1 45–51

Richoux JP, Cordonnier JL, Bouhnik J, Clauser E, Corvol P, Menard J and Grignon G 1983 Immuno-cytochemical localization of angiotensinogen in rat liver and kidney Cell Tissue Res 233 2 439–51

Rimola A, Londono MC, Guevara G, Bruguera M, Navasa M, Forns X, Garcia-Retortillo M, Garcia-Valdecasas JC and Rodes J 2004 Beneficial effect of angiotensin-blocking agents on graft fibrosis in hepatitis C recurrence after liver transplantation Transplantation 78 5 686–91

Rincon-Sanchez AR, Covarrubias A, Rivas-Estilla AM, Pedraza-Chaverrri J, Cruz C, Islas-Carbajal MC, Panduro A, Estanes A and Armendariz-Borunda J 2005 PGE2 alleviates kidney and liver damage, decreases plasma renin activity and acute phase response in cirrhotic rats with acute liver damage Exp Toxicol Pathol 56 4-5 291–303

Rivera-Huizar S, Rincon-Sanchez AR, Covarrubias-Pinedo A, Islas-Carbajal MC, Gabriel-Ortiz G, Pedraza-Chaverrri J, Alvarez-Rodriguez A, Meza-Garcia E and Armendariz-Borunda J 2006 Renal dysfunction as a consequence of acute liver damage by bile duct ligation in cirrhotic rats Exp Toxicol Pathol 58 2-3 185–95
Ron D, Brasier AR and Habener JF 1990 Transcriptional regulation of hepatic angiotensinogen gene expression by the acute-phase response *Mol Cell Endocrinol* 74 3 C97–104

Russo FP, Alison MR, Bigger BW, Amofah E, Florou A, Amin F, Bou-Gharios G, Jeffery R, Iredale JP and Forbes SJ 2006 The bone marrow functionally contributes to liver fibrosis *Gastroenterology* 130 6 1807–21

Sakata T, Takenaga N, Endoh T, Wada O and Matsuki K 1991 Diagnostic significance of serum angiotensin-converting enzyme activity in biochemical tests with special reference of chronic liver diseases *Jpn J Med* 30 5 402–7

Santos RA, Simoes e Silva AC, Maric C, Silva DM, Machado RP, de Buhr I, Heringer-Walther S, Pinheiro SV, Lopes MT, Bader M, Mendes EP, Lemos VS, Campagnole-Santos MJ, Schultheiss HP, Speth R and Walther T 2003 Angiotensin-(1-7) is an endogenous ligand for the G protein-coupled receptor Mas *Proc Natl Acad Sci U S A* 100 14 8258–63

Sasaki K, Taniguchi M, Miyoshi M, Goto O, Sato K and Watanabe T 2005 Are transcription factors NF-kappaB and AP-1 involved in the ANG II-stimulated production of proinflammatory cytokines induced by LPS in dehydrated rats? *Am J Physiol Regul Integr Comp Physiol* 289 6 R1599–608

Sawa H 1990 [Angiotensinogen: gene expression and protein localization in human tissues] *Hokkaido Igaku Zasshi* 65 2 189–99

Schiavone MT, Santos RA, Brosnihan KB, Khosla MC and Ferrario CM 1988 Release of vasopressin from the rat hypothalamo-neurohypophysial system by angiotensin-(1-7) heptapeptide *Proc Natl Acad Sci U S A* 85 11 4095–8

Schuppan D, Ruehl M, Somasundaram R and Hahn EG 2001 Matrix as a modulator of hepatic fibrogenesis *Semin Liver Dis* 21 3 351–72

Sewnath ME, van der Poll T, van Noorden CJ, ten Kate FJ and Gouma DJ 2004 Cholestatic interleukin-6-deficient mice succumb to endotoxin-induced liver injury and pulmonary inflammation *Am J Respir Crit Care Med* 169 3 413–20

Silva DM, Vianna HR, Cortes SF, Campagnole-Santos MJ, Santos RA and Lemos VS 2006 Evidence for a new angiotensin-(1-7) receptor subtype in the aorta of Sprague-Dawley rats *Peptides*

Strawn WB, Ferrario CM and Tallant EA 1999 Angiotensin-(1-7) reduces smooth muscle growth after vascular injury *Hypertension* 33 1 Pt 2 207–11

Tallant EA, Ferrario CM and Gallagher PE 2005 Angiotensin-(1-7) inhibits growth of cardiac myocytes through activation of the mas receptor *Am J Physiol Heart Circ Physiol* 289 4 H1560–6

Thomas MC and Tikellis C 2005 ACE2: an ACE up the Sleeve *Current enzyme inhibition* 1 51–63

Tigerstedt R BP 1898 Niere und Kreislauf *Skand Arch Physiol*. 8 223–271

Timmermans PB, Benfield P, Chiu AT, Herblin WF, Wong PC and Smith RD 1992 Angiotensin II receptors and functional correlates *Am J Hypertens* 5 12 Pt 2 221S–235S

Timmermans PB, Chiu AT, Herblin WF, Wong PC and Smith RD 1992 Angiotensin II receptor subtypes *Am J Hypertens* 5 6 Pt 1 406–10

Tipnis SR, Hooper NM, Hyde R, Karran E, Christie G and Turner AJ 2000 A human homolog of angiotensin-converting enzyme. Cloning and functional expression as a captopril-insensitive carboxypeptidase *J Biol Chem* 275 43 33238–43

Toblli JE, Ferder L, Stella I, Angerosa M and Inserra F 2002 Enalapril prevents fatty liver in nephrotic rats *J Nephrol* 15 4 358–67

Tuncer I, Ozbek H, Ugras S and Bayram I 2003 Anti-fibrogenic effects of captopril and candesartan cilexetil on the hepatic fibrosis development in rat. The effect of AT1-R blocker on the hepatic fibrosis *Exp Toxicol Pathol* 55 2-3 159–66

Turner AJ 2003 Exploring the structure and function of zinc metallopeptidases: old enzymes and new discoveries *Biochem Soc Trans* 31 Pt 3 723–7

Ueda S, Masumori-Maemoto S, Wada A, Ishii M, Brosnihan KB and Umemura S 2001 Angiotensin(1-7) potentiates bradykinin-induced vasodilatation in man *J Hypertens* 19 11 2001–9

Vickers C, Hales P, Kaushik V, Dick L, Gavin J, Tang J, Godbout K, Parsons T, Baronas E, Hsieh F, Acton S, Patane M, Nichols A and Tummino P 2002 Hydrolysis of biological peptides by human angiotensin-converting enzyme-related carboxypeptidase *J Biol Chem* 277 17 14838–43
Vlachogiannakos J, Tang AK, Patch D and Burroughs AK 2001 Angiotensin converting enzyme inhibitors and angiotensin II antagonists as therapy in chronic liver disease Gut 49 2 303–8
von Bohlen und Halbach O 2003 Angiotensin IV in the central nervous system Cell Tissue Res 311 1–9
Walters PE, Gaspari TA and Widdop RE 2005 Angiotensin-(1-7) acts as a vasodepressor agent via angiotensin II type 2 receptors in conscious rats Hypertension 45 5 960–6
Wang XZ, Zhang LJ, Li D, Huang YH, Chen ZX and Li B 2003 Effects of transmitters and interleukin-10 on rat hepatic fibrosis induced by CCl4 World J Gastroenterol 9 3 539–43
Warner FJ, Lew RA, Smith AI, Lambert DW, Hooper NM and Turner AJ 2005 Angiotensin-converting enzyme 2 (ACE2), but not ACE, is preferentially localized to the apical surface of polarized kidney cells J Biol Chem 280 47 39353–62
Warner FJ, Smith AI, Hooper NM and Turner AJ 2004 Angiotensin-converting enzyme-2: a molecular and cellular perspective Cell Mol Life Sci 61 21 2704–13
Wei H, Li D, Lu H, Zhan Y, Wang Z, Huang X, Pan Q and Xu Q 2000 Effects of angiotensin II receptor blockade on hepatic fibrosis in rats Zhonghua Gan Zang Bing Za Zhi 8 5 302–4
Wei HS, Lu HM, Li DG, Zhan YT, Wang ZR, Huang X, Cheng JL and Xu QF 2000 The regulatory role of AT 1 receptor on activated HSCs in hepatic fibrogenesis:effects of RAS inhibitors on hepatic fibrosis induced by CCl(4) World J Gastroenterol 6 6 824–828
Wei YH, Jun L and Qiang CJ 2004 Effect of losartan, an angiotensin II antagonist, on hepatic fibrosis induced by CCl4 in rats Dig Dis Sci 49 10 1589–94
Whalen R, Rockey DC, Friedman SL and Boyer TD 1999 Activation of rat hepatic stellate cells leads to loss of glutathione S-transferases and their enzymatic activity against products of oxidative stress Hepatology 30 4 927–33
Yang L, Bataller R, Dulyx J, Coffman TM, Gines P, Rippe RA and Brenner DA 2005 Attenuated hepatic inflammation and fibrosis in angiotensin type 1a receptor deficient mice J Hepatol 43 2 317–23
Yokohama S, Tokusashi Y, Nakamura K, Tamaki Y, Okamoto S, Okada M, Aso K, Hasegawa T, Aoshima M, Miyokawa N, Haneda M and Yoneda M 2006 Inhibitory effect of angiotensin II receptor antagonist on hepatic stellate cell activation in non-alcoholic steatohepatitis World J Gastroenterol 12 2 322–6
Yokohama S, Yoneda M, Haneda M, Okamoto S, Okada M, Aso K, Hasegawa T, Tokusashi Y, Miyokawa N and Nakamura K 2004 Therapeutic efficacy of an angiotensin II receptor antagonist in patients with nonalcoholic steatohepatitis Hepatology 40 5 1222–5
Yoshiji H, Kuriyama S and Fukui H 2002 Angiotensin-I-converting enzyme inhibitors may be an alternative anti-angiogenic strategy in the treatment of liver fibrosis and hepatocellular carcinoma. Possible role of vascular endothelial growth factor Tumour Biol 23 6 348–56
Yoshiji H, Kuriyama S, Kawata M, Yoshii J, Ikenaka Y, Noguchi R, Nakatani T, Tsujinoue H and Fukui H 2001 The angiotensin-I-converting enzyme inhibitor perindopril suppresses tumor growth and angiogenesis: possible role of the vascular endothelial growth factor Clin Cancer Res 7 4 1073–8
Yoshiji H, Kuriyama S, Yoshii J, Ikenaka Y, Noguchi R, Nakatani T, Tsujinoue H and Fukui H 2001 Angiotensin-II type 1 receptor interaction is a major regulator for liver fibrosis development in rats Hepatology 34 4 Pt 1 745–50
Yoshiji H, Kuriyama S, Yoshii J, Ikenaka Y, Noguchi R, Yamase K, Namisaki T, Yamazaki M, Tsujinoue H, Imazu H and Fukui H 2003 Angiotensin-II induces the tissue inhibitor of metalloproteinases-1 through the protein kinase-C signaling pathway in rat liver fibrosis development Hepatol Res 27 1 51–56
Yoshiji H, Noguchi R and Fukui H 2005 Combined effect of an ACE inhibitor, perindopril, and interferon on liver fibrosis markers in patients with chronic hepatitis C J Gastroenterol 40 2 215–6
Yoshiji H, Noguchi R, Kuriyama S, Yoshii J and Ikenaka Y 2005 Combination of interferon and angiotensin-converting enzyme inhibitor, perindopril, suppresses liver carcinogenesis and angiogenesis in mice Oncol Rep 13 3 491–5
Yoshiji H, Yoshii J, Ikenaka Y, Noguchi R, Tsujinoue H, Nakatani T, Imazu H, Yamase K, Kuriyama S and Fukui H 2002 Inhibition of renin-angiotensin system attenuates liver enzyme-altered preneoplastic lesions and fibrosis development in rats J Hepatol 37 1 22–30
Yoshiji H, Yoshii J, Ikenaka Y, Noguchi R, Yanase K, Tsujinoue H, Imazu H and Fukui H 2002 Suppression of the renin-angiotensin system attenuates vascular endothelial growth factor-mediated tumor development and angiogenesis in murine hepatocellular carcinoma cells *Int J Oncol* 20 **6** 1227–31

Zhang X, Yu WP, Gao L, Wei KB, Ju JL and Xu JZ 2004 Effects of lipopolysaccharides stimulated Kupffer cells on activation of rat hepatic stellate cells *World J Gastroenterol* 10 **4** 610–3

Zhang Y, Yang X, Wu P, Xu L, Liao G and Yang G 2003 Expression of angiotensin II type 1 receptor in rat hepatic stellate cells and its effects on cell growth and collagen production *Horm Res* 60 **3** 105–10

Zhang YJ, Yang XS, Wu PS, Li X, Zhang XF, Chen XQ and Yu ZX 2003 Effects of angiotensin II and losartan on the growth and proliferation of hepatic stellate cells *Di Yi Jun Yi Da Xue Xue Bao* 23 **3** 219–21, 227

Zisman LS, Keller RS, Weaver B, Lin Q, Speth R, Bristow MR and Canver CC 2003 Increased angiotensin-(1-7)-forming activity in failing human heart ventricles: evidence for upregulation of the angiotensin-converting enzyme Homologue ACE2 *Circulation* 108 **14** 1707–12

Zisman LS, Meixell GE, Bristow MR and Canver CC 2003 Angiotensin-(1-7) formation in the intact human heart: in vivo dependence on angiotensin II as substrate *Circulation* 108 **14** 1679–81